Stock_Titan Posted - 5 days ago

$THTX Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting https://www.stocktitan.net/news/THTX/theratechnologies-to-present-long-term-efficacy-safety-and-tgqt0f1c41n0.html

LabRat78 Posted - 04/29/24

$THTX Looks like Christian will be presenting at the ADC Toxicity Summit on July 23rd. https://adc-toxicity.com/?utm_source=external&utm_medium=event-listing&utm_campaign=event-listing&utm_content=media-partner/evvnt/paid/ev-46355 "Targeting Sortilin (SORT1) to Unlock the Potential of Peptide Drug Conjugates (PDCs) in Oncology: Rapid Internalization within Minutes with Unique Multimodal MOA & Safety Profile • Understand the rationale for targeting the SORT1 receptor in cancer • Discuss the unique toxicity profile of sudocetaxel zendusortide (TH1902), the lead PDC from Theratechnologies’ SORT1+ Technology™ platform, that differs substantially from the safety profile of taxanes, due to the multimodal MOA of the conjugate and the low levels of free circulating docetaxel • Discuss how this multifaceted MOA with improved safety profile can lead to prolonged regression of disease and enable combinations with ADCs, PDCs and other anti-cancer therapies • Discuss the ongoing phase I clinical development of sudocetaxel zendusortide, focusing on dose optimization"

LabRat78 Posted - 04/23/24

$THTX TH1902 gets a mention... to me the timing smells ripe on the sortilin front. Just a matter of time. Any coincidence two deal focused board members have been put forward? I think not https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1331231/full

Stock_Titan Posted - 04/15/24

$THTX Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders https://www.stocktitan.net/news/THTX/theratechnologies-announces-mailing-of-management-proxy-circular-in-ymcqkk052mik.html

Stock_Titan Posted - 04/11/24

$THTX Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference https://www.stocktitan.net/news/THTX/theratechnologies-to-present-at-the-2024-bloom-burton-co-healthcare-vtvg972ph3bf.html

Annaba514 Posted - 04/10/24

$THTX compagny of shiit..

mikesterz7 Posted - 04/10/24

$THTX Q1 Earnings: Loss of $4.5 million ( 10 cents per share ) Revenue of $16.2 million

Robie7 Posted - 04/10/24

$THTX why did sales drop so much? Was this expected?

lecorb Posted - 04/10/24

$THTX Theratechnologies Q1 EPS $(0.10) Beats $(0.12) Estimate, Sales $16.25M Miss $20.10M Estimate 7:32 am ET April 10, 2024 (Benzinga) Theratechnologies (NASDAQ:THTX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.12) by 16.67 percent. This is a 77.27 percent increase over losses of $(0.44) per share from the same period last year. The company reported quarterly sales of $16.25 million which missed the analyst consensus estimate of $20.10 million by 19.17 percent. This is a 18.39 percent decrease over sales of $19.91 million the same period last year.

BullFisher00 Posted - 04/10/24

$THTX idk how this is up premarket. They kept guidance the same but shit the bed so hard this quarter- didnt even come close to expectations, so i have HUGE doubts they can meet those revenue goals. Still only 1 patient in second phase of dosing.

DonCorleone77 Posted - 04/10/24

$THTX Theratechnologies sees FY24 revenue $87M-$90M, consensus $88.22M The company said, "Our anticipated FY2024 revenue guidance range is confirmed between $87 million and $90 million, or growth of the commercial portfolio in the range of 6.4% and 10.0%, as compared to the 2023 fiscal year results. We anticipate Adjusted EBITDA, a non-IFRS measure, to be between $13 and $15 million for fiscal 2024."

DonCorleone77 Posted - 04/10/24

$THTX 2 of 2 - Theratechnologies reports Q1 EPS (10c), consensus (12c) ....Despite lower revenues this quarter, we expect a reverse trend in the second quarter and an evening out of revenues in the second half of 2024. We continue to demonstrate strength on the bottom line, with an improved net loss of $4.4 million versus a net loss of $10.4 million in Q1 2023. This quarter also marks our third consecutive quarter of near-flat-to-positive Adjusted EBITDA, up more than $3.6 million2 from Q1 2023."

DonCorleone77 Posted - 04/10/24

$THTX 1 of 2 - Theratechnologies reports Q1 EPS (10c), consensus (12c) Reports Q1 revenue $16.247M, consensus $20.1M. "I am pleased to wrap up the quarter by reaffirming our full year 2024 guidance of revenues between $87 and $90 million and an Adjusted EBITDA in the range of $13-15 million. Our new cost structure together with our strategic focus on commercial capabilities puts Theratechnologies on the brink of producing stronger cash flow and value for shareholders," said Paul Levesque, President and Chief Executive Officer at Theratechnologies. "EGRIFTA SV continues to be our engine of growth and according to key performance metrics such as enrollments and unique patients, we are on track to achieve and even surpass our long-term objectives. As anticipated during our recent fourth quarter call, we are experiencing some variability in revenue growth reporting based on the buildup and subsequent drawdown of inventories in the early part of fiscal 2023....

epsguid Posted - 04/10/24

$THTX reported a loss of $0.10 via @eWhispers http://eps.sh/d/thtx

Stock_Titan Posted - 04/10/24

$THTX Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024 https://www.stocktitan.net/news/THTX/theratechnologies-reports-financial-results-and-provides-business-4fyj4kro64yk.html

dylantheinvestor Posted - 04/09/24

$THTX sensing something a little special tomorrow, last month looked solid… just a guess

LabRat78 Posted - 04/09/24

$THTX Fairly interesting preclinical work... when combined with some further data in the Ph1 trial, this thing is poised to moved. The critics and complainers have been loud, but it will be interesting when that tide turns. Earnings tomorrow and then perhaps some insider activity to follow? Reminder, THTX insiders have likely been in blackout since late November due to year end financials that roll directly into the end of Q1. So unless there is a pending deal or data about to be released, I would assume this is when the window finally opens for them...

DonCorleone77 Posted - 04/08/24

$THTX 2 of 2 - Theratechnologies announces data presentation of SORT1+ technology at AACR ...."The preclinical data presented at AACR add to the sizeable body of evidence supporting the potential utility of the SORT1+ Technology platform as an engine for the development of novel peptide-drug conjugates to treat various types of cancer," said Christian Marsolais Ph.D., Senior Vice President and Chief Medical Officer at Theratechnologies. "In addition to our lead peptide-drug conjugate, sudocetaxel zendusortide, these latest data highlight the promising tolerability and anti-tumor effects of our investigational camptothecin-peptide conjugates, further demonstrating the versatility and flexibility of the platform. We welcome discussions with potential partners who are interested in the further development of these innovative therapies."

DonCorleone77 Posted - 04/08/24

$THTX 1 of 2 - Theratechnologies announces data presentation of SORT1+ technology at AACR Theratechnologies presented preclinical data that highlight the versatility and flexibility of the Company's SORT1+ Technology platform. In a poster session at the 2024 annual meeting of the American Association for Cancer Research AACR in San Diego, Calif., researchers reported that Theratechnologies' investigational camptothecin-peptide conjugates are well tolerated and associated with significant tumor regression in colorectal cancer CRC and triple-negative breast cancer TNBC xenograft models. The study also demonstrated synergistic anti-tumor efficacy and good tolerability with the combination of two peptide drug conjugates with different payloads....

Stock_Titan Posted - 04/08/24

$THTX Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform https://www.stocktitan.net/news/THTX/theratechnologies-preclinical-data-presentation-at-aacr-2024-ovv80svqs2ue.html

Stock_Titan Posted - 1 month ago

$THTX Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update https://www.stocktitan.net/news/THTX/theratechnologies-to-announce-first-quarter-2024-financial-results-w3ddek7h6fei.html

Stock_Titan Posted - 03/28/24

$THTX Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform https://www.stocktitan.net/news/THTX/theratechnologies-to-present-preclinical-data-at-aacr-on-multiple-pd-28sl147urkrl.html

Stock_Titan Posted - 03/22/24

$THTX Theratechnologies Announces Update on its Preclinical Oncology Research Program https://www.stocktitan.net/news/THTX/theratechnologies-announces-update-on-its-preclinical-oncology-ol6fxz4u09j3.html

TickerDD_com Posted - 03/21/24

From 3/8/2024, looking back across 22 Month-Ends for THTX, Percentage Change of Average Monthly Price had Equal (50%) while Percentage Change of Average Monthly Volume had All Positives (100%) $THTX #THTX #THTXStock #TickerDD https://www.youtube.com/watch?v=_CzgecXQOzo

Stock_Titan Posted - 03/21/24

$THTX Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer https://www.stocktitan.net/news/THTX/theratechnologies-initiates-increased-dose-level-in-phase-1-clinical-f44dnowe0grc.html

BillBtheBull Posted - 03/13/24

$THTX Thera is the biggest pile of dog shit, anything they can screw up they will. The POS CEO just paid himself a $405k bonus for driving the company value down -80% last year and the arrogant French Canadian fucks remain silent through it all as has been their way for years… FU Thera

BullFisher00 Posted - 03/08/24

$THTX this is the biggest issue with this stock. We have no volume, so when someone wants out they tank us. Valuation nearing half our yearly revenue.

BillBtheBull Posted - 2 months ago

$THTX Theratechnologies is such a disaster, everything that they can screw up, they do screw up. Only way this recovers is if TH1902 turns into a miracle and the entire board gets shit canned, including that overpaid good for nothing CEO. -90% over 3 years. Tight work

Americanbulls Posted - 2 months ago

$THTX the bull pattern is confirmed & a BUY signal is issued @ www.Americanbulls.com/SignalPage.aspx?lang=en&Ticker=THTX. Buy Level: 1.51 Target: 1.99

Americanbulls Posted - 2 months ago

$THTX may go up 32% if the bull pattern is confirmed. Check confirmation [55%] @ www.Americanbulls.com/SignalPage.aspx?lang=en&Ticker=THTX. Buy level:1.50.